Search Beyond News…

MarketsandMarkets projects oligonucleotide synthesis market to more than double by 2031, driven by expanding therapeutic and diagnostic applications

Executive summary: MarketsandMarkets released a forecast that the global oligonucleotide synthesis market will reach USD 32.72 billion by 2031, up from USD 14.64 billion in 2026. The projected doubling of market size signals rising capital investment in oligo‑based therapeutics and diagnostics, affecting suppliers, biotech firms and healthcare spending.

Who is involved: MarketsandMarkets (analyst firm), oligonucleotide synthesis providers (e.g., IDT, Twist Bioscience, Thermo Fisher), and end‑users in pharma and diagnostics.

Likely next: Companies will likely announce capacity expansions and new GMP‑grade facilities to meet the anticipated demand, with quarterly updates expected throughout 2027‑2028.

The report estimates the market will grow from USD 14.64 billion in 2026 to USD 32.72 billion in 2031, a CAGR of 17.4 %. This expansion reflects increased demand for oligos in mRNA‑based vaccines, gene therapies and molecular diagnostics. The forecast assumes continued adoption of synthetic biology tools and a stable regulatory environment for oligonucleotide drugs.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Key entities

Sources

Related cases

Browse the full archive →